Fresenius Kabi is offering PEMEtrexed for Injection.
The medication, which is a generic of Alimta, is used for adult patients with non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
[Read More: Fresenius Kabi debuts smaller-dose fentanyl citrate injection]
Available in four presentations for intravenous use, Fresenius Kabi said that it now has the broadest portfolio of PEMEtrexed for Injection products available from any manufacturer in the United States, including two new strengths designed to help streamline pharmacy operations and reduce drug waste:
- PEMEtrexed for Injection, 100 mg per single-dose vial;
- PEMEtrexed for Injection, 500 mg per single-dose vial;
- New strength: PEMEtrexed for Injection, 750 mg per single-dose vial; and
- New strength: PEMEtrexed for Injection, 1 g per single-dose vial
“We are pleased to introduce another generic chemotherapy medication to help make cancer treatments more accessible and affordable for patients,” said John Ducker, president and CEO of Fresenius Kabi USA. “And we’re proudly producing our PEMEtrexed for Injection here in the U.S.”
[Read More: Fresenius Kabi rolls out generic Torisel]
PEMEtrexed for Injection, along with other oncology medicines, is part of the company’s KabiConnect program, a recent expansion of its KabiCare patient support program that offers co-pay assistance to eligible U.S. patients.
The program can lower out-of-pocket costs to as little as $0 per month for eligible patients. To determine eligibility, patients should speak to their physician. Enrollment is a simple online process, the company said.